A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

Prior treatment

• Have received or are receiving targeted ANGPTL3 treatment within 5 months or 5 half-lives, whichever is longer, prior to screening;
• Weight change of more than 10% in the 4 weeks prior to randomisation;
• Initiation of a new dietary plan or significant differences from previous dietary structure and habits within 4 weeks prior to screening;
• History of major surgery within 12 weeks prior to baseline, or planning to undergo major surgery during the study;

Other illness

• Presence of uncontrolled endocrine disease affecting lipids or lipoproteins;
• Uncontrolled hypertension (blood pressure \> 160/100 mmHg at screening);
• Known allergy to any component of the study drug.

Lab values

• Fasting TG ≥ 4.5 mmol/L at screening;
• New York Heart Association (NYHA) class IV heart failure or left ventricular ejection fraction \<30% within 12 months prior to screening;

Other

• Women who are pregnant (including planned pregnancies) or breastfeeding;
• Refusal to limit alcohol consumption to moderate limits and below during the study period, specifically no more than 14 units per week;

• Male or female aged ≥ 12 years and weighing ≥ 40 kg at the time of ICF signature;
• Patients with HoFH who meet genetic or clinical diagnosis;
• Willing to follow a daily low-fat diet for the duration of the study;
• Receiving stable and tolerable lipid-lowering therapy prior to LDL-C testing during the screening period;
• Fasting LDL-C ≥ 2.6 mmol/L.